Ocugen has finished dosing all 63 participants in its Phase 2/3 GARDian3 trial for OCU410ST, a one‑time subretinal gene therapy that targets every ABCA4 mutation linked to Stargardt disease. The milestone was reached earlier than the original schedule, giving the company a head start on the third‑quarter 2026 interim analysis and the planned 2027 Biologics License Application filing.
The GARDian3 study is a multicenter, randomized, masked trial that enrolls patients with Stargardt disease and randomizes them to receive a single subretinal injection of OCU410ST or to serve as untreated controls. The primary endpoint is the reduction in atrophic retinal lesion growth at 12 months. The trial’s design and early dosing completion reduce the time needed to generate the data that will support regulatory submission.
OCU410ST delivers the RORA gene via an AAV5 vector, aiming to restore nuclear hormone receptor signaling and address multiple disease pathways, including lipofuscin accumulation, oxidative stress, complement activation, and inflammation. Phase 1 data from the earlier GARDian 1 trial showed a 54 % reduction in lesion growth at 12 months and stabilization or improvement in visual function in all treated eyes.
The trial’s success is particularly meaningful because Stargardt disease affects roughly 100,000 patients in the United States and Europe and currently has no approved therapies. By completing dosing early, Ocugen is de‑risking the program and positioning itself to meet the 2027 BLA filing target, a key milestone in its strategy to file three BLAs by 2028.
Dr. Shankar Musunuri, Ocugen’s Chairman and CEO, said, "This enrollment milestone for a pivotal trial underscores the tremendous progress our team is making toward bringing a transformative therapy to people living with multiple ABCA4‑related gene mutations including Stargardt disease. The efficient and accelerated execution of this trial reflects the strong engagement of investigators and patients. It reinforces our confidence in OCU410ST as a potential one‑time treatment option for all Stargardt patients who are desperately seeking rescue from blindness with no approved therapies to date." Dr. Huma Qamar, Chief Medical Officer, added, "I am encouraged by the enthusiastic response and rapid enrollment in the GARDian3 registrational clinical trial for Stargardt disease—a devastating pediatric‑onset retinal disorder affecting approximately 100,000 patients in the U.S. and Europe."
Ocugen’s broader pipeline includes OCU400 for retinitis pigmentosa and OCU410 for geographic atrophy, underscoring the company’s focus on rare retinal diseases. The early dosing milestone for OCU410ST strengthens the overall portfolio and supports the company’s goal of advancing multiple gene‑therapy candidates toward regulatory approval.
The announcement has been well received by investors, reflecting confidence in Ocugen’s clinical strategy and the potential impact of a first‑in‑class therapy for a large orphan market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.